Respondent Understanding in Discrete Choice Experiments : A Scoping Review

Acknowledgements The authors would like to acknowledge the contributions of Brendan Mulhern, who gave feedback on the initial project proposal and helped with the full-text reviews, and Bernadette Carr, the librarian who gave assistance developing and implementing the search strategy. Funding During part of this project, Alison Pearce was supported by a University of Technology Sydney Chancellor’s Postdoctoral Research Fellowship and the University of Technology Sydney International Researcher Development Scheme. Mark Harrison is supported by a Michael Smith Foundation for Health Research Scholar Award 2017 (#16813), and holds the UBC Professorship in Sustainable Health Care, which, between 2014 and 2017, was funded by Amgen Canada, AstraZeneca Canada, Eli Lilly Canada, GlaxoSmithKline, Merck Canada, Novartis Pharmaceuticals Canada, Pfizer Canada, Boehringer Ingelheim (Canada), Hoffman-La Roche, LifeScan Canada, and Lundbeck Canada. The Health Economics Research Unit (HERU) receives funding from the Chief Scientist Office (CSO) of the Scottish Government Health and Social Care Directorates.Peer reviewedPublisher PD

Exploring the validity of estimating EQ-5D and SF-6D utility values from the health assessment questionnaire in patients with inflammatory arthritis

<p>Abstract</p> <p>Background</p> <p>Utility scores are used to estimate Quality Adjusted Life Years (QALYs), applied in determining the cost-effectiveness of health care interventions. In studies where no preference based measures are collected, indirect methods have been developed to estimate utilities from clinical instruments. The aim of this study was to evaluate a published method of estimating the EuroQol-5D (EQ-5D) and Short Form-6D (SF-6D) (preference based) utility scores from the Health Assessment Questionnaire (HAQ) in patients with inflammatory arthritis.</p> <p>Methods</p> <p>Data were used from 3 cohorts of patients with: early inflammatory arthritis (<10 weeks duration); established (>5 years duration) stable rheumatoid arthritis (RA); and RA being treated with anti-TNF therapy. Patients completed the EQ-5D, SF-6D and HAQ at baseline and a follow-up assessment. EQ-5D and SF-6D scores were predicted from the HAQ using a published method. Differences between predicted and observed EQ-5D and SF-6D scores were assessed using the paired t-test and linear regression.</p> <p>Results</p> <p>Predicted utility scores were generally higher than observed scores (range of differences: EQ-5D 0.01 - 0.06; SF-6D 0.05 - 0.10). Change between predicted values of the EQ-5D and SF-6D corresponded well with observed change in patients with established RA. Change in predicted SF-6D scores was, however, less than half of that in observed values (p < 0.001) in patients with more active disease. Predicted EQ-5D scores underestimated change in cohorts of patients with more active disease.</p> <p>Conclusion</p> <p>Predicted utility scores overestimated baseline values but underestimated change. Predicting utility values from the HAQ will therefore likely underestimate the QALYs of interventions, particularly for patients with active disease. We recommend the inclusion of at least one preference based measure in future clinical studies.</p

Exploring the Cost Effectiveness of Shared Decision Making for Choosing between Disease-Modifying Drugs for Relapsing-Remitting Multiple Sclerosis in the Netherlands:A State Transition Model

Background Up to 31% of patients with relapsing-remitting multiple sclerosis (RRMS) discontinue treatment with disease-modifying drug (DMD) within the first year, and of the patients who do continue, about 40% are nonadherent. Shared decision making may decrease nonadherence and discontinuation rates, but evidence in the context of RRMS is limited. Shared decision making may, however, come at additional costs. This study aimed to explore the potential cost-effectiveness of shared decision making for RRMS in comparison with usual care, from a (limited) societal perspective over a lifetime. Methods An exploratory economic evaluation was conducted by adapting a previously developed state transition model that evaluates the cost-effectiveness of a range of DMDs for RRMS in comparison with the best supportive care. Three potential effects of shared decision making were explored: 1) a change in the initial DMD chosen, 2) a decrease in the patient's discontinuation in using the DMD, and 3) an increase in adherence to the DMD. One-way and probabilistic sensitivity analyses of a scenario that combined the 3 effects were conducted. Results Each effect separately and the 3 effects combined resulted in higher quality-adjusted life years (QALYs) and costs due to the increased utilization of DMD. A decrease in discontinuation of DMDs influenced the incremental cost-effectiveness ratio (ICER) most. The combined scenario resulted in an ICER of euro17,875 per QALY gained. The ICER was sensitive to changes in several parameters. Conclusion This study suggests that shared decision making for DMDs could potentially be cost-effective, especially if shared decision making would help to decrease treatment discontinuation. Our results, however, may depend on the assumed effects on treatment choice, persistence, and adherence, which are actually largely unknown

The financial cost of doctors emigrating from sub-Saharan Africa: human capital analysis

Objective To estimate the lost investment of domestically educated doctors migrating from sub-Saharan African countries to Australia, Canada, the United Kingdom, and the United States

The Complexity of Transferring Remote Monitoring and Virtual Care Technology Between Countries: Lessons From an International Workshop

International deployment of remote monitoring and virtual care (RMVC) technologies would efficiently harness their positive impact on outcomes. Since Canada and the United Kingdom have similar populations, health care systems, and digital health landscapes, transferring digital health innovations between them should be relatively straightforward. Yet examples of successful attempts are scarce. In a workshop, we identified 6 differences that may complicate RMVC transfer between Canada and the United Kingdom and provided recommendations for addressing them. These key differences include (1) minority groups, (2) physical geography, (3) clinical pathways, (4) value propositions, (5) governmental priorities and support for digital innovation, and (6) regulatory pathways. We detail 4 broad recommendations to plan for sustainability, including the need to formally consider how highlighted country-specific recommendations may impact RMVC and contingency planning to overcome challenges; the need to map which pathways are available as an innovator to support cross-country transfer; the need to report on and apply learnings from regulatory barriers and facilitators so that everyone may benefit; and the need to explore existing guidance to successfully transfer digital health solutions while developing further guidance (eg, extending the nonadoption, abandonment, scale-up, spread, sustainability framework for cross-country transfer). Finally, we present an ecosystem readiness checklist. Considering these recommendations will contribute to successful international deployment and an increased positive impact of RMVC technologies. Future directions should consider characterizing additional complexities associated with global transfer

Canadian Valuation of EQ-5D Health States: Preliminary Value Set and Considerations for Future Valuation Studies

Background The EQ-5D is a preference based instrument which provides a description of a respondent's health status, and an empirically derived value for that health state often from a representative sample of the general population. It is commonly used to derive Quality Adjusted Life Year calculations (QALY) in economic evaluations. However, values for health states have been found to differ between countries. The objective of this study was to develop a set of values for the EQ-5D health states for use in Canada. Methods Values for 48 different EQ-5D health states were elicited using the Time Trade Off (TTO) via a web survey in English. A random effect model was fitted to the data to estimate values for all 243 health states of the EQ-5D. Various model specifications were explored. Comparisons with EQ-5D values from the UK and US were made. Sensitivity analysis explored different transformations of values worse than dead, and exclusion criteria of subjects. Results The final model was estimated from the values of 1145 subjects with socio-demographics broadly representative of Canadian general population with the exception of Quebec. This yielded a good fit with observed TTO values, with an overall R2 of 0.403 and a mean absolute error of 0.044. Conclusion A preference-weight algorithm for Canadian studies that include the EQ-5D is developed. The primary limitations regarded the representativeness of the final sample, given the language used (English only), the method of recruitment, and the difficulty in the task. Insights into potential issues for conducting valuation studies in countries as large and diverse as Canada are gained

Decentralized Automated Dispensing Devices: Systematic Review of Clinical and Economic Impacts in Hospitals

ABSTRACTBackground: Technologies have been developed over the past 20 years to automate the stages of drug distribution in hospitals, including ordering, dispensing, delivery, and administration of medications, in attempts to decrease medication error rates. Decentralized automated dispensing devices (ADDs) represent one such technology that is being adopted by hospitals across Canada, but the touted benefits, in terms of improved patient safety and cost savings, are increasingly being questioned.Objective: To summarize and evaluate the existing literature reporting the clinical and economic impacts of using decentralized ADDs in hospitals.Data Sources: A literature search was conducted in MEDLINE, Embase, and all evidence-based medicine databases for the years 1992 to 2012 to identify English-language articles reporting on the use of ADDs in hospital wards. Study Selection and Data Extraction: All randomized controlled trials, observational studies, before-and-after studies, time series analyses, cost-effectiveness and cost–benefit analyses, and review articles were considered for inclusion. Studies evaluating pharmacy-based ADDs, such as bar code–based medication dispensing carousels, automated dispensing shelves, and combinations of various dispensing modalities, were excluded.Data Synthesis: Of 175 studies initially identified, 8 were retained for evidence synthesis. It appears that ADDs were effective in reducing medication storage errors and the time that nurses spent taking inventory of narcotics and controlled substances. There was no definitive evidence that using ADDs increased the time that nurses or pharmacists spent with patients, reduced medication errors resulting in patient harm, or reduced costs in Canadian hospitals. However, pharmacy technicians spent more time stocking the machines.Conclusion: ADDs have limited potential to decrease medication errors and increase efficiencies, but their impact is highly institution-specific, and use of this technology requires proper integration into an institution’s medication distribution process. Before deploying this technology, it is recommended that  Canadian hospitals carefully examine their current systems and the benefits they hope to gain with the changes. RÉSUMÉContexte : Au cours des vingt dernières années, des  technologies ont été développées afin d’automatiser les étapes de la distribution des médicaments dans les hôpitaux, notamment pour ce qui est de l’émission d’ordonnances et de la dispensation, de la délivrance et de l’administration des médicaments, le tout dans le but de réduire le nombre d’erreurs de médication. Les cabinets automatisés décentralisés (CAD) font partie de ces technologies qui sont adoptées par les hôpitaux du Canada, mais leurs bienfaits très publicisés, en ce qui a trait à l’amélioration de la sécurité des patients et aux économies pouvant être réalisées, sont de plus en plus remis en question.Objectif : Résumer et évaluer la littérature faisant état des retombées cliniques et économiques de l’utilisation de CAD dans les hôpitaux. Sources des données : Une recherche documentaire a été effectuée dans MEDLINE, Embase ainsi que dans l’ensemble des bases de données médicales fondées sur des preuves pour la période allant de 1992 à 2012 afin de trouver les articles rédigés en anglais qui font état de l’utilisation des CAD dans les services d’hôpitaux.Sélection des études et extraction des données : Cette revue a pris en considération toutes les études cliniques aléatoires, les études observationnelles, les études avant-après, les analyses de séries chronologiques, les analyses coût-avantage et coût-efficacité, et les articles de synthèse. Les études évaluant les CAD en usage dans les pharmacies, robots parmi lesquels on compte les carrousels de distribution de médicaments utilisant des codes-barres, les rayonnages de distribution automatisés et les combinaisons de différents moyens de distribution, n’ont pas été retenues.Synthèse des données : Des 175 études d’abord recensées, huit ont été retenues pour la synthèse des données probantes. Les CAD semblent avoir été utiles pour réduire le nombre d’erreurs d’entreposage de médicaments ainsi que le temps nécessaire au personnel infirmier pour faire l’inventaire des narcotiques et des substances contrôlées. Aucune donnée probante ne permet d’affirmer que le temps passé par le personnel infirmier et les pharmaciens auprès des patients a augmenté, que le nombre d’erreurs de médication causant du tort aux patients a baissé ou que les coûts des hôpitaux canadiens ont chuté grâce à l’utilisation des CAD. Par contre, les techniciens en pharmacie ont passé plus de temps à remplir les machines.Conclusion : Les CAD présentent un faible potentiel de réduction du nombre d’erreurs de médication et d’augmentation de l’efficacité des ressources. Cependant, leur incidence est propre à chaque établissement et l’utilisation de cette technologie nécessite une intégration réfléchie dans le processus de distribution des médicaments d’un établissement. Avant de mettre en place cette technologie, il est recommandé aux hôpitaux canadiens de bien étudier leurs systèmes actuels et de réfléchir aux avantages qu’ils espèrent obtenir par ce changement